TheraSphere With Durvalumab and Tremelimumab for HCC
Active, not recruiting · Phase 2 · NCT05063565
Conditions: Hepatocellular Carcinoma
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 15
- Sites paid
- 15
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Boston Scientific Corporation (with Biocompatibles UK Ltd)
- Tested
- TheraSphere Y-90 glass microsphere therapy (device), Durvalumab (Imfinzi) immunotherapy (drug), Tremelimumab immunotherapy (drug)
- Dates
- Started 2023-11-03; completion 2027-06
- Results posted
- Not yet
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $1.7M in research payments for this study in 2025 (114 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gregory J. Woodhead, M.D., PH.D. Interventional Radiology · Tucson, AZ
- Adam Burgoyne, M.D., PH.D. Hematology & Oncology · San Diego, CA
- Huat Chye Lim, MD Internal Medicine · San Francisco, CA
- Reetu Mukherji, M.D. Hematology & Oncology · Washington, DC
- Beau Toskich, MD Interventional Radiology · Jacksonville, FL
- Audrey E. Kam, M.D. Hematology & Oncology · Chicago, IL
- Paul M. Haste, M.D. Interventional Radiology · Indianapolis, IN
- Lingling Du, M.D. Hematology & Oncology · New Orleans, LA
- Siobhan M. Flanagan, M.D. Interventional Radiology · Minneapolis, MN
- Joseph D. Giardina, MD Interventional Radiology · Minneapolis, MN
- Nina Beri, M.D. Hematology & Oncology · New York, NY
- Aiwu R. He, MD, PHD Medical Oncology · New York, NY
- Linda Y. Wu, MD Medical Oncology · New York, NY
- Anjana A. Pillai, M.D. Gastroenterology · Cleveland, OH
- Ramya Thota, MBBS Hematology & Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $525,993
- Ochsner Medical Center Acute, LA $259,194
- Georgetown University $256,618
- Mayo Clinic Jacksonville $197,946
- The Regents of University of California $150,732
- University of Chicago $54,802
- Regents of the University of Minnesota $52,180
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $49,337
- Intermountain Health Utah Valley Hospital, UT $48,366
- University of Arizona $43,810
- New York University School of Medicine $30,581
- Rush University Medical Center, IL $20,899
- Columbia University $7,500
- Rush University Medical Center $5,551
- Indiana University $2,709
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.